Jason Clark

发表

JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.

J. Bendell, F. Dawkins, E. O’Reilly, 2015 .

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

Robert A. Beckman, Jason Clark, Cong Chen, 2011, Nature Reviews Drug Discovery.

Acknowledgement

D. Busch, H. Einsele, M. Dhodapkar, 1987, Hearing Research.

First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

P. O'dwyer, P. Scherle, T. Gajewski, 2017, Clinical Cancer Research.

Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.

P. O'dwyer, T. Gajewski, L. Leopold, 2013 .

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

G. Ciliberto, J. Marshall, N. La Monica, 2013, Journal of Translational Medicine.

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Baselga, J. Tabernero, J. Hardwick, 2011, Clinical Cancer Research.

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.

M. Arcasoy, S. Verstovsek, M. Talpaz, 2021, Clinical lymphoma, myeloma & leukemia.

Cancer Therapy : Clinical A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab ( MK-0646 ) , an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody , in Patients with Advanced Solid Tumors

J. Tabernero, S. Cosimo, J. Hardwick, 2011 .

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

S. Verstovsek, R. Hoffman, R. Paquette, 2017, Haematologica.

Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.

K. Ouriel, G. Tepe, S. Duda, 2004, Journal of vascular and interventional radiology : JVIR.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J. Nemunaitis, H. Hurwitz, Z. Wainberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

Jason Clark, K. Flaherty, G. Wilding, 2011, Cancer Chemotherapy and Pharmacology.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

M. Hidalgo, E. Van Cutsem, H. Hurwitz, 2018, Investigational New Drugs.

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

D. Cho, J. Janik, R. Kristeleit, 2022, Journal for ImmunoTherapy of Cancer.

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

C. Wouters, R. Saurenmann, N. Wulffraat, 2007, Arthritis and rheumatism.

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Nikhil Uppal, Jason Clark, Philip J. Stella, 2014 .

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

S. Verstovsek, R. Hoffman, R. Paquette, 2014 .

Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

G. Ciliberto, J. Marshall, N. La Monica, 2013, Journal of Translational Medicine.

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

M. Hidalgo, H. Hurwitz, C. Verslype, 2017 .